Cargando…

Switching α-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients

BACKGROUND AND OBJECTIVES: In this study we examined the effects of switching α-glucosidase inhibitors (α-GI) from acarbose or voglibose to miglitol on glucose fluctuations and circulating concentrations of cardiovascular disease risk factors, such as soluble adhesion molecules (sE-selectin, sICAM-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hariya, Natsuyo, Mochizuki, Kazuki, Inoue, Seiya, Saito, Miyoko, Fuchigami, Masahiro, Goda, Toshinao, Osonoi, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153962/ https://www.ncbi.nlm.nih.gov/pubmed/25079671 http://dx.doi.org/10.1007/s40268-014-0055-7

Ejemplares similares

S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy
por: Kondo, Shinnosuke, et al.
Publicado: (2021)

Regulation of Carbohydrate-Responsive Metabolic Genes by Histone Acetylation and the Acetylated Histone Reader BRD4 in the Gene Body Region
por: Mochizuki, Kazuki, et al.
Publicado: (2021)

BRD4 regulates adiponectin gene induction by recruiting the P-TEFb complex to the transcribed region of the gene
por: Sakurai, Naoko, et al.
Publicado: (2017)

Medium-chain fatty acids enhance expression and histone acetylation of genes related to lipid metabolism in insulin-resistant adipocytes
por: Kawamura, Musashi, et al.
Publicado: (2022)

Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
por: Osonoi, Takeshi, et al.
Publicado: (2019)

Epigenomic-basis of Preemptive Medicine for Neurodevelopmental Disorders
por: Kubota, Takeo, et al.
Publicado: (2015)

Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion
por: Lee, Eun Young, et al.
Publicado: (2015)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi, Takeshi, et al.
Publicado: (2020)

Efficacy of ipragliflozin as monotherapy or as add‐on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics
por: Osonoi, Takeshi, et al.
Publicado: (2017)

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study
por: Shimabukuro, Michio, et al.
Publicado: (2017)

Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome
por: Amagai, Mari, et al.
Publicado: (2017)

Prader-Willi Syndrome: The Disease that Opened up Epigenomic-Based Preemptive Medicine
por: Kubota, Takeo, et al.
Publicado: (2016)

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Glucose and TNF enhance expression of TNF and IL1B, and histone H3 acetylation and K4/K36 methylation, in juvenile macrophage cells
por: Honma, Kazue, et al.
Publicado: (2020)

Poor sleep quality is associated with increased arterial stiffness in Japanese patients with type 2 diabetes mellitus
por: Osonoi, Yusuke, et al.
Publicado: (2015)

Stability-Indicating RP-HPLC Method for Estimation of Miglitol in Bulk and Tablets
por: Shrivastava, B., et al.
Publicado: (2010)

Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2012)

Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients
por: Kubo, Sayaka, et al.
Publicado: (2010)

Review: Miglitol has potential as a therapeutic drug against obesity
por: Sugimoto, Satoru, et al.
Publicado: (2015)

The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice
por: Hamada, Yoji, et al.
Publicado: (2020)

Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia
por: Kitano, Daisuke, et al.
Publicado: (2013)

Breakfast skipping is associated with persistently increased arterial stiffness in patients with type 2 diabetes
por: Mita, Tomoya, et al.
Publicado: (2020)

Morphological, biochemical, transcriptional and epigenetic responses to fasting and refeeding in intestine of Xenopus laevis
por: Tamaoki, Keiji, et al.
Publicado: (2016)

Transcription elongation factor Brd4-P-TEFb accelerates intestinal differentiation-associated SLC2A5 gene expression
por: Inamochi, Yuko, et al.
Publicado: (2016)

Kinetic Determination of Acarbose and Miglitol in Bulk and Pharmaceutical Formulations Using Alkaline Potassium Permanganate
por: Ibrahim, F. A., et al.
Publicado: (2007)

Lower intake of saturated fatty acids is associated with persistently higher arterial stiffness in patients with type 2 diabetes
por: Mita, Tomoya, et al.
Publicado: (2020)

Effect of Hemodialysis on Plasma Glucose Profile and Plasma Level of Liraglutide in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease: A Pilot Study
por: Osonoi, Takeshi, et al.
Publicado: (2014)

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Development and Validation of Miglitol and Its Impurities by RP-HPLC and Characterization Using Mass Spectrometry Techniques
por: Balakumaran, Kesavan, et al.
Publicado: (2016)

Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model
por: Kishida, Yumi, et al.
Publicado: (2017)

Miglitol increases energy expenditure by upregulating uncoupling protein 1 of brown adipose tissue and reduces obesity in dietary-induced obese mice
por: Sugimoto, Satoru, et al.
Publicado: (2014)

Relationships between lifestyle patterns and cardio-renal-metabolic parameters in patients with type 2 diabetes mellitus: A cross-sectional study
por: Ogihara, Takeshi, et al.
Publicado: (2017)

Four‐year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes
por: Kobori, Mariko, et al.
Publicado: (2016)

Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus
por: Nomura, Shosaku, et al.
Publicado: (2011)

Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial
por: Iijima, Takahiro, et al.
Publicado: (2020)

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Relationship between dietary patterns and risk factors for cardiovascular disease in patients with type 2 diabetes mellitus: a cross-sectional study
por: Osonoi, Yusuke, et al.
Publicado: (2016)

Relationships Among Conventional Cardiovascular Risk Factors and Lifestyle Habits With Arterial Stiffness in Type 2 Diabetic Patients
por: Hamamura, Misako, et al.
Publicado: (2017)

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas
por: Hsieh, Sheng-Hwu, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_i0jeg17g22qr07cuqlih4blj3h